Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 4
2004 8
2005 8
2006 9
2007 12
2008 13
2009 18
2010 25
2011 31
2012 26
2013 24
2014 34
2015 47
2016 42
2017 41
2018 52
2019 51
2020 71
2021 75
2022 7
Text availability
Article attribute
Article type
Publication date

Search Results

537 results
Results by year
Filters applied: . Clear all
Page 1
Chemistry-First Approach for Nomination of Personalized Treatment in Lung Cancer.
McMillan EA, Ryu MJ, Diep CH, Mendiratta S, Clemenceau JR, Vaden RM, Kim JH, Motoyaji T, Covington KR, Peyton M, Huffman K, Wu X, Girard L, Sung Y, Chen PH, Mallipeddi PL, Lee JY, Hanson J, Voruganti S, Yu Y, Park S, Sudderth J, DeSevo C, Muzny DM, Doddapaneni H, Gazdar A, Gibbs RA, Hwang TH, Heymach JV, Wistuba I, Coombes KR, Williams NS, Wheeler DA, MacMillan JB, Deberardinis RJ, Roth MG, Posner BA, Minna JD, Kim HS, White MA. McMillan EA, et al. Among authors: wu x. Cell. 2018 May 3;173(4):864-878.e29. doi: 10.1016/j.cell.2018.03.028. Epub 2018 Apr 19. Cell. 2018. PMID: 29681454 Free PMC article.
Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial.
Chen X, Wu X, Wu H, Gu Y, Shao Y, Shao Q, Zhu F, Li X, Qian X, Hu J, Zhao F, Mao W, Sun J, Wang J, Han G, Li C, Xia Y, Seesaha PK, Zhu D, Li H, Zhang J, Wang G, Wang X, Li X, Shu Y. Chen X, et al. Among authors: wu x. J Immunother Cancer. 2020 Nov;8(2):e001240. doi: 10.1136/jitc-2020-001240. J Immunother Cancer. 2020. PMID: 33172881 Free PMC article. Clinical Trial.
Catalytic inverse vulcanization.
Wu X, Smith JA, Petcher S, Zhang B, Parker DJ, Griffin JM, Hasell T. Wu X, et al. Nat Commun. 2019 Feb 7;10(1):647. doi: 10.1038/s41467-019-08430-8. Nat Commun. 2019. PMID: 30733431 Free PMC article.
537 results